validated that HDAC inhibitor, fimepinostat, could restore EGFR expression in SNU‐2962A cells and their organoid model and augment the sensitivity of SCLC to EGFR‐TKI both in vitro and in vivo models. This evidence concerns the gene HDAC9 and small cell lung carcinoma.